In METABRIC, CBFB mutations predicted improved ER+ overall survival (HR, 0.52; P = 9.3 × 10 <sup>-5</sup> ).<h4>Conclusions</h4>CBFB mutations identify ∼5% of ER+ breast cancers with exceptional ET benefit. The gene discussed is CBFB; the disease is breast carcinoma.